Leukemia, Myelomonocytic, Chronic
"Leukemia, Myelomonocytic, Chronic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.
MeSH Number(s)
C04.557.337.539.522
C15.378.190.615.510
Concept/Terms
Leukemia, Myelomonocytic, Chronic- Leukemia, Myelomonocytic, Chronic
- Myelomonocytic Leukemia, Chronic
- Chronic Myelomonocytic Leukemia
- Chronic Myelomonocytic Leukemias
- Leukemia, Chronic Myelomonocytic
- Leukemias, Chronic Myelomonocytic
- Myelomonocytic Leukemias, Chronic
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myelomonocytic, Chronic".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myelomonocytic, Chronic".
This graph shows the total number of publications written about "Leukemia, Myelomonocytic, Chronic" by people in Harvard Catalyst Profiles by year, and whether "Leukemia, Myelomonocytic, Chronic" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1996 | 2 | 0 | 2 |
1997 | 0 | 1 | 1 |
1998 | 1 | 0 | 1 |
1999 | 1 | 0 | 1 |
2001 | 1 | 1 | 2 |
2003 | 1 | 0 | 1 |
2005 | 0 | 2 | 2 |
2006 | 1 | 1 | 2 |
2007 | 3 | 0 | 3 |
2008 | 1 | 0 | 1 |
2009 | 3 | 0 | 3 |
2010 | 1 | 0 | 1 |
2011 | 2 | 0 | 2 |
2012 | 1 | 0 | 1 |
2013 | 1 | 0 | 1 |
2015 | 2 | 0 | 2 |
2017 | 5 | 0 | 5 |
2018 | 2 | 0 | 2 |
2019 | 4 | 0 | 4 |
2020 | 6 | 0 | 6 |
2021 | 3 | 0 | 3 |
2022 | 6 | 0 | 6 |
2023 | 5 | 0 | 5 |
2024 | 1 | 0 | 1 |
Below are the most recent publications written about "Leukemia, Myelomonocytic, Chronic" by people in Profiles.
-
Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies. Leuk Lymphoma. 2024 Apr; 65(4):503-510.
-
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol. 2024 Feb; 99(2):E32-E36.
-
Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based study. Leuk Lymphoma. 2023 Dec; 64(13):2156-2164.
-
A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia. Br J Haematol. 2023 04; 201(2):302-307.
-
Molecular assessment and the current limits of post-transplant prognostication for chronic myelomonocytic leukemia. Haematologica. 2023 01 01; 108(1):3-4.
-
The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica. 2023 01 01; 108(1):150-160.
-
Progenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse Outcomes. Blood Cancer Discov. 2022 11 02; 3(6):536-553.
-
Hematoma Formation After Hip Corticosteroid Injection in a Patient with Chronic Myelomonocytic Leukemia: A Case Report. JBJS Case Connect. 2022 Apr 01; 12(2).
-
Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia. Nat Commun. 2022 03 17; 13(1):1434.
-
Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better? Am J Hematol. 2022 05; 97(5):E185-E188.